This work not only uncovers the epigenetic regulatory mechanism of tumor cGAS, but also reveals the immunomodulatory roles of VC and TET2 in liver cancer, providing a strategy to induce tumor vascular normalization and a scientific rationale for further clinical trials combining VC with immunotherapy. The gene discussed is CGAS; the disease is liver cancer.